SC 13G/A | 2024-02-13 | RENAISSANCE TECHNOLOGIES LLC | Vanda Pharmaceuticals Inc. | 3,681,125 | 6.4% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Vanda Pharmaceuticals Inc. | 3,456,087 | 6.0% | EDGAR |
SC 13G/A | 2024-02-09 | DIMENSIONAL FUND ADVISORS LP | Vanda Pharmaceuticals Inc. | 1,967,985 | 3.4% | EDGAR |
SC 13G/A | 2024-01-23 | BlackRock Inc. | Vanda Pharmaceuticals Inc. | 8,346,367 | 14.5% | EDGAR |
SC 13G/A | 2024-01-22 | STATE STREET CORP | Vanda Pharmaceuticals Inc. | - | 2.1% | EDGAR |
SC 13G/A | 2023-10-06 | BlackRock Inc. | Vanda Pharmaceuticals Inc. | 6,759,117 | 11.8% | EDGAR |
SC 13G/A | 2023-02-14 | MACQUARIE GROUP LTD | Vanda Pharmaceuticals Inc. | 1,323,547 | 2.3% | EDGAR |
SC 13G/A | 2023-02-14 | Palo Alto Investors LP | Vanda Pharmaceuticals Inc. | 1,087,064 | 1.4% | EDGAR |
SC 13G/A | 2023-02-13 | RENAISSANCE TECHNOLOGIES LLC | Vanda Pharmaceuticals Inc. | 2,889,425 | 5.1% | EDGAR |
SC 13G | 2023-02-10 | DIMENSIONAL FUND ADVISORS LP | Vanda Pharmaceuticals Inc. | 2,853,832 | 5.0% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Vanda Pharmaceuticals Inc. | 3,992,166 | 7.0% | EDGAR |
SC 13G/A | 2023-02-07 | STATE STREET CORP | Vanda Pharmaceuticals Inc. | - | 6.6% | EDGAR |
SC 13G/A | 2023-01-24 | BlackRock Inc. | Vanda Pharmaceuticals Inc. | 10,326,614 | 18.2% | EDGAR |
SC 13G/A | 2022-02-15 | ARMISTICE CAPITAL, LLC | Vanda Pharmaceuticals Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2022-02-14 | STATE STREET CORP | Vanda Pharmaceuticals Inc. | - | 6.0% | EDGAR |
SC 13G/A | 2022-02-14 | MACQUARIE GROUP LTD | Vanda Pharmaceuticals Inc. | 2,913,471 | 5.2% | EDGAR |
SC 13G/A | 2022-02-14 | Palo Alto Investors LP | Vanda Pharmaceuticals Inc. | 2,834,244 | 5.1% | EDGAR |
SC 13G/A | 2022-02-11 | RENAISSANCE TECHNOLOGIES LLC | Vanda Pharmaceuticals Inc. | 3,212,214 | 5.8% | EDGAR |
SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | Vanda Pharmaceuticals Inc. | 3,876,684 | 7.0% | EDGAR |
SC 13G/A | 2022-01-27 | BlackRock Inc. | Vanda Pharmaceuticals Inc. | 9,825,375 | 17.6% | EDGAR |